Find out if you have a Strattera® liver claim
Strattera® has been linked to liver damage side effects in two ADHD patients per reports by the FDA. The FDA has asked the manufacturer, Eli Lilly, to augment the drug’s label with a “bolded” warning about severe liver injury. The new warning label indicates that severe liver injury may progress to liver failure resulting in death or the need for a liver transplant in a small percentage of patients.
Eli Lilly has warned doctors to stop prescribing Strattera® in patients with jaundice or existing liver damage. The updated warning and labeling follows reports of liver problems in an adult and a teenager who had been treated with Strattera for several months. According to Eli Lilly, both patients recovered after discontinuing the drug.
Strattera® is the only non-stimulant drug for attention-deficit/hyperactivity disorder. The ADHD prescription medication is also known as amoxetine HCl.
Two million people have used Strattera® since the U.S. FDA approved it in November 2002 for the treatment of attention deficit disorder in children, adolescents and adults.